AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 38878997 — intervention group
Group type: EXPERIMENTAL
Intervention: TOPPS intervention (values-based, behavioral activation intervention)
Number of subjects: 250
Study 38878997 — intervention group
Group type: COMPARATOR
Intervention: Health Education (HE) control condition
Number of subjects: 250
Study 38879045 — intervention group
Group type: EXPERIMENTAL
Intervention: Through-the-needle injection-capable electrosurgical knife
Number of subjects: 579
Study 38879382 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 to 6 metastatic mesogastria
Number of subjects: 479
Study 38879382 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 metastatic mesogastrium
Number of subjects: 479
Study 38879382 — intervention group
Group type: EXPERIMENTAL
Intervention: No lymph node metastasis
Number of subjects: 479
Study 38879382 — intervention group
Group type: EXPERIMENTAL
Intervention: Metastatic mesogastria
Number of subjects: 479
Study 38879382 — intervention group
Group type: EXPERIMENTAL
Intervention: N stages
Number of subjects: 479
Study 38879393 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorlatinib 100 mg once daily (cohort 1)
Number of subjects: 109
Study 38879393 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorlatinib 100 mg once daily (cohort 2)
Number of subjects: 109
Study 38879455 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine Learning (ML) pulse oximetry combining oxygenation, perfusion data, and pulse delay at 2 time points
Number of subjects: 6
Study 38879455 — intervention group
Group type: EXPERIMENTAL
Intervention: ML algorithms at 1 versus 2 time points with/without pulse delay
Number of subjects: 6
Study 38879462 — intervention group
Group type: EXPERIMENTAL
Intervention: Perivascular adipose tissue attenuation around LIMA in situ
Number of subjects: 573
Study 38879462 — intervention group
Group type: COMPARATOR
Intervention: Perivascular adipose tissue attenuation around native coronary arteries
Number of subjects: 573
Study 38879476 — intervention group
Group type: EXPERIMENTAL
Intervention: PET imaging for radiotherapy planning
Number of subjects: 0
Study 38879506 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemodynamic management with HPI guidance
Number of subjects: 60
Study 38879506 — intervention group
Group type: COMPARATOR
Intervention: Standard of care treatment
Number of subjects: 60
Study 38879518 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed Cold-Stored Platelets (DCSP) - ABO-identical, buffy-coat, pathogen-reduced platelets in platelet additive solution maintained at 22 °C for up to 4 days then placed at 4 °C for a minimum of 24 h, with expiration at 14 days after collection. Duration: from termination of cardiopulmonary bypass to 24 h after, with a maximum of two doses.
Number of subjects: 50
Study 38879518 — intervention group
Group type: COMPARATOR
Intervention: Room Temperature Platelets (RTP) - standard of care control group.
Number of subjects: 50
Study 38879518 — intervention group
Group type: EXPERIMENTAL
Intervention: DCSP
Number of subjects: 50
Study 38879520 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleeve Gastrectomy (SG)
Number of subjects: 26
Study 38879520 — intervention group
Group type: EXPERIMENTAL
Intervention: Roux-en-Y Gastric Bypass (RYGB)
Number of subjects: 26
Study 38879520 — intervention group
Group type: EXPERIMENTAL
Intervention: Both SG and RYGB
Number of subjects: 26
Study 38879532 — intervention group
Group type: EXPERIMENTAL
Intervention: ACP care pathway implementation
Number of subjects: 13
Study 38879532 — intervention group
Group type: EXPERIMENTAL
Intervention: ACP care pathway structure and tools
Number of subjects: 13
Study 38879532 — intervention group
Group type: EXPERIMENTAL
Intervention: Integration of ACP pathway with current practice
Number of subjects: 13
Study 38879532 — intervention group
Group type: EXPERIMENTAL
Intervention: Support for ACP and the pathway
Number of subjects: 13
Study 38879559 — intervention group
Group type: EXPERIMENTAL
Intervention: RYGB
Number of subjects: 38
Study 38879559 — intervention group
Group type: COMPARATOR
Intervention: SG
Number of subjects: 38
Study 38879561 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary team conferences (MDTs)
Number of subjects: 112
Study 38879571 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg Pycnogenol® daily for 12 weeks
Number of subjects: 150
Study 38879571 — intervention group
Group type: COMPARATOR
Intervention: Placebo daily for 12 weeks
Number of subjects: 150
Study 38879802 — intervention group
Group type: EXPERIMENTAL
Intervention: Linvoseltamab 200 mg
Number of subjects: 221
Study 38879802 — intervention group
Group type: EXPERIMENTAL
Intervention: Linvoseltamab 50 mg
Number of subjects: 221
Study 38879879 — intervention group
Group type: EXPERIMENTAL
Intervention: SPS tablets (n = 60; three tablets per dose, twice daily) for 24 weeks
Number of subjects: 121
Study 38879879 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 61) for 24 weeks
Number of subjects: 121
Study 38880111 — intervention group
Group type: EXPERIMENTAL
Intervention: RH5.1/Matrix-M vaccine candidate (10 μg RH5.1 at 0, 1, and 2 months for Adults 10M; 50 μg RH5.1 at 0 and 1 month and 10 μg RH5.1 at 6 months for Adults DFx; 10 μg RH5.1 at 0, 1, and 2 months for Children 10M; 10 μg RH5.1 at 0, 1, and 6 months for Children 10D; Children DFx and High Children DFx with dose-escalation regimen)
Number of subjects: 60
Study 38880111 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed third dose regimen (Children 10D)
Number of subjects: 60
Study 38880111 — intervention group
Group type: EXPERIMENTAL
Intervention: RH5.1/Matrix-M vaccine candidate
Number of subjects: 60
Study 38880172 — intervention group
Group type: EXPERIMENTAL
Intervention: EGFR mutations
Number of subjects: 601
Study 38880172 — intervention group
Group type: EXPERIMENTAL
Intervention: EGFR mutation subtypes
Number of subjects: 601
Study 38880172 — intervention group
Group type: COMPARATOR
Intervention: Nonsmoking status
Number of subjects: 601
Study 38880172 — intervention group
Group type: COMPARATOR
Intervention: Stage of NSCLC
Number of subjects: 601
Study 38880172 — intervention group
Group type: EXPERIMENTAL
Intervention: Age, gender, ethnicity
Number of subjects: 601
Study 38880172 — intervention group
Group type: COMPARATOR
Intervention: Smoking history and stage III disease
Number of subjects: 601
Study 38880172 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic adjuvant therapy
Number of subjects: 601
Study 38880172 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemoradiotherapy
Number of subjects: 601
Study 38880174 — intervention group
Group type: EXPERIMENTAL
Intervention: Refined corn meal + corn bran (RCM + B)
Number of subjects: 36
Study 38880174 — intervention group
Group type: COMPARATOR
Intervention: Whole-grain corn meal
Number of subjects: 36
Study 38880174 — intervention group
Group type: COMPARATOR
Intervention: Refined corn meal (RCM)
Number of subjects: 36
Study 38880198 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose (200 ppm for 30 min) + continuous low-dose (20 ppm) iNO
Number of subjects: 20
Study 38880198 — intervention group
Group type: COMPARATOR
Intervention: Intermittent high-dose iNO
Number of subjects: 20
Study 38880251 — intervention group
Group type: EXPERIMENTAL
Intervention: dupilumab 300 mg every 2 weeks
Number of subjects: 89
Study 38880251 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 89
Study 38880279 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary ciliary dyskinesia (PCD)
Number of subjects: 1000
Study 38880279 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of upper airway disease (chronic rhinosinusitis and/or nasal polyps)
Number of subjects: 1000
Study 38880279 — intervention group
Group type: EXPERIMENTAL
Intervention: Age < 53 years
Number of subjects: 1000
Study 38880279 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiologic involvement of any middle and lower lobe
Number of subjects: 1000
Study 38880279 — intervention group
Group type: EXPERIMENTAL
Intervention: Duration of bronchiectasis > 15 years
Number of subjects: 1000
Study 38880279 — intervention group
Group type: EXPERIMENTAL
Intervention: History of Pseudomonas aeruginosa isolation from respiratory specimen
Number of subjects: 1000
Study 38880785 — intervention group
Group type: EXPERIMENTAL
Intervention: Ad26.RSV.preF/RSV preF protein vaccine (1 × 10 dose)
Number of subjects: 0
Study 38880785 — intervention group
Group type: EXPERIMENTAL
Intervention: Ad26.RSV.preF/RSV preF protein vaccine
Number of subjects: 0
Study 38880822 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin
Number of subjects: 2604
Study 38880902 — intervention group
Group type: EXPERIMENTAL
Intervention: One-stage endoscopic middle meatal antrostomy (EMMA) with the application of platelet-rich fibrin (PRF) membranes and acrylic splint
Number of subjects: 9
Study 38880932 — intervention group
Group type: EXPERIMENTAL
Intervention: BI 474121 (3.0 mg/kg)
Number of subjects: 0
Study 38880932 — intervention group
Group type: EXPERIMENTAL
Intervention: BI 474121
Number of subjects: 0
Study 38880954 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based intervention (MBI), 30-min sessions, three times a week for 8 weeks during haemodialysis
Number of subjects: 61
Study 38880954 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based intervention (MBI)
Number of subjects: 61
Study 38880954 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 61
Study 38880956 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib (5 or 10 mg twice daily)
Number of subjects: 1202
Study 38880956 — intervention group
Group type: COMPARATOR
Intervention: TNFi
Number of subjects: 1202
Study 38881232 — intervention group
Group type: EXPERIMENTAL
Intervention: Young patients (yCRC)
Number of subjects: 1599
Study 38881232 — intervention group
Group type: COMPARATOR
Intervention: Elderly patients (eCRC)
Number of subjects: 1599
Study 38881232 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (yCRC and eCRC)
Number of subjects: 1599
Study 38881252 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Number of subjects: 0
Study 38881252 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 38881370 — intervention group
Group type: EXPERIMENTAL
Intervention: Edoxaban management during periprocedural period
Number of subjects: 0
Study 38881370 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 38881386 — intervention group
Group type: EXPERIMENTAL
Intervention: Invasive mechanical ventilation
Number of subjects: 0
Study 38881397 — intervention group
Group type: EXPERIMENTAL
Intervention: Staff-assisted peritoneal dialysis (PD)
Number of subjects: 121
Study 38881460 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive blood pressure control (target <120 mm Hg)
Number of subjects: 502
Study 38881460 — intervention group
Group type: COMPARATOR
Intervention: Standard blood pressure control (target <140 mm Hg)
Number of subjects: 502
Study 38881506 — intervention group
Group type: EXPERIMENTAL
Intervention: Heplisav-B (HepB-CpG) 2-dose series
Number of subjects: 96
Study 38881506 — intervention group
Group type: EXPERIMENTAL
Intervention: Heplisav-B (HepB-CpG) 1-dose
Number of subjects: 96
Study 38881599 — intervention group
Group type: EXPERIMENTAL
Intervention: EYP-1901 (440 μg, 1030 μg, 2060 μg, 3090 μg)
Number of subjects: 17
Study 38881600 — intervention group
Group type: EXPERIMENTAL
Intervention: PRIMA neurostimulation system with a subretinal microchip
Number of subjects: 5
Study 38881832 — intervention group
Group type: EXPERIMENTAL
Intervention: Spatial-to-Temporal Attention Module (STAM)
Number of subjects: 0
Study 38881832 — intervention group
Group type: COMPARATOR
Intervention: Facial features only
Number of subjects: 0
Study 38881900 — intervention group
Group type: EXPERIMENTAL
Intervention: Cibisatamab
Number of subjects: 0
Study 38881900 — intervention group
Group type: COMPARATOR
Intervention: Monoclonal anti-idiotypic (anti-ID) antibody positive controls
Number of subjects: 0
Study 38882206 — intervention group
Group type: EXPERIMENTAL
Intervention: High postexercise cTn concentrations (n=100)
Number of subjects: 1500
Study 38882206 — intervention group
Group type: COMPARATOR
Intervention: Low postexercise cTn concentrations (n=50)
Number of subjects: 1500
Study 38882206 — intervention group
Group type: EXPERIMENTAL
Intervention: Entire cohort (n=1500)
Number of subjects: 1500
Study 38882443 — intervention group
Group type: EXPERIMENTAL
Intervention: Hetrombopag
Number of subjects: 60
Study 38882443 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 38882712 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking stress test
Number of subjects: 24
Study 38883150 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 5 mg BID monotherapy
Number of subjects: 1000
Study 38883163 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated analysis of genetic, epigenetic, and immunophenotypic landscape
Number of subjects: 61
Study 38883706 — intervention group
Group type: EXPERIMENTAL
Intervention: CONCERN Early Warning System (EWS) intervention
Number of subjects: 60893
Study 38883706 — intervention group
Group type: COMPARATOR
Intervention: usual-care
Number of subjects: 60893
Study 38883737 — intervention group
Group type: EXPERIMENTAL
Intervention: Silver diamine fluoride (SDF) with fluoride varnish
Number of subjects: 1083
Study 38883737 — intervention group
Group type: COMPARATOR
Intervention: Sealants and atraumatic restorations (ART) with fluoride varnish
Number of subjects: 1083
Study 38883740 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribociclib (CDK4/6 inhibitor) and Everolimus (mTOR inhibitor)
Number of subjects: 24
Study 38883743 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-administered intravaginal 5% fluorouracil (5FU) cream, 2g every other week for eight applications.
Number of subjects: 12
Study 38883743 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-administered intravaginal 5% fluorouracil (5FU) cream
Number of subjects: 12
Study 38883760 — intervention group
Group type: EXPERIMENTAL
Intervention: Game-based rehabilitation program with scaffolding (17 subjects)
Number of subjects: 33
Study 38883760 — intervention group
Group type: COMPARATOR
Intervention: Game-based rehabilitation program without scaffolding (16 subjects)
Number of subjects: 33
Study 38883760 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (combined)
Number of subjects: 33
Study 38883767 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative physical activity
Number of subjects: 0
Study 38883767 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 38883779 — intervention group
Group type: EXPERIMENTAL
Intervention: Intratumoral administration of anti-CD40 agonistic antibody (2141-V11)
Number of subjects: 10
Study 38883789 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized sexual dysfunction (SD) screening intervention
Number of subjects: 86
Study 38883792 — intervention group
Group type: EXPERIMENTAL
Intervention: Immune checkpoint inhibitors (ICI)
Number of subjects: 748
Study 38883792 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk score based on identified parameters
Number of subjects: 748
Study 38883792 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk score used prospectively in external French cohort
Number of subjects: 748
Study 38883796 — intervention group
Group type: EXPERIMENTAL
Intervention: Retention strategies implemented by the TEDDY Study
Number of subjects: 0
Study 38883796 — intervention group
Group type: EXPERIMENTAL
Intervention: Unique retention strategies of TEDDY
Number of subjects: 0
Study 38884175 — intervention group
Group type: EXPERIMENTAL
Intervention: Crovalimab
Number of subjects: 204
Study 38884175 — intervention group
Group type: COMPARATOR
Intervention: Eculizumab
Number of subjects: 204
Study 38884254 — intervention group
Group type: EXPERIMENTAL
Intervention: Futibatinib
Number of subjects: 0
Study 38884324 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenecteplase (0.25 mg/kg, max 25 mg)
Number of subjects: 516
Study 38884324 — intervention group
Group type: COMPARATOR
Intervention: Standard medical treatment
Number of subjects: 516
Study 38884324 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenecteplase
Number of subjects: 516
Study 38884332 — intervention group
Group type: EXPERIMENTAL
Intervention: Reteplase (18 mg bolus followed by another 18 mg bolus 30 minutes later)
Number of subjects: 1412
Study 38884332 — intervention group
Group type: COMPARATOR
Intervention: Alteplase (0.9 mg/kg, max 90 mg)
Number of subjects: 1412
Study 38884332 — intervention group
Group type: EXPERIMENTAL
Intervention: Reteplase
Number of subjects: 1412
Study 38884332 — intervention group
Group type: COMPARATOR
Intervention: Alteplase
Number of subjects: 1412
Study 38884347 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based intervention (34 communities)
Number of subjects: 67
Study 38884347 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control (33 communities)
Number of subjects: 67
Study 38884347 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention (34 communities)
Number of subjects: 67
Study 38884415 — intervention group
Group type: EXPERIMENTAL
Intervention: Thromboprophylaxis (not specified in detail)
Number of subjects: 1836
Study 38884415 — intervention group
Group type: EXPERIMENTAL
Intervention: Inappropriate thromboprophylaxis practices
Number of subjects: 1836
Study 38884415 — intervention group
Group type: EXPERIMENTAL
Intervention: Specialized clinical pathway for thromboprophylaxis
Number of subjects: 1836
Study 38884880 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication optimization intervention
Number of subjects: 285
Study 38884880 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 285
Study 38884900 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan (T-DXd)
Number of subjects: 213
Study 38884900 — intervention group
Group type: COMPARATOR
Intervention: Treatment of physician's choice (TPC)
Number of subjects: 213
Study 38884967 — intervention group
Group type: EXPERIMENTAL
Intervention: MRT plus FIs
Number of subjects: 126
Study 38884967 — intervention group
Group type: COMPARATOR
Intervention: MRT
Number of subjects: 126
Study 38884982 — intervention group
Group type: EXPERIMENTAL
Intervention: Povidone iodine in alcohol
Number of subjects: 3360
Study 38884982 — intervention group
Group type: COMPARATOR
Intervention: Chlorhexidine gluconate in alcohol
Number of subjects: 3360
Study 38884982 — intervention group
Group type: EXPERIMENTAL
Intervention: Povidone iodine in alcohol (cardiac surgery)
Number of subjects: 3360
Study 38884982 — intervention group
Group type: COMPARATOR
Intervention: Chlorhexidine gluconate in alcohol (cardiac surgery)
Number of subjects: 3360
Study 38884982 — intervention group
Group type: EXPERIMENTAL
Intervention: Povidone iodine in alcohol (abdominal surgery)
Number of subjects: 3360
Study 38884982 — intervention group
Group type: COMPARATOR
Intervention: Chlorhexidine gluconate in alcohol (abdominal surgery)
Number of subjects: 3360
Study 38884987 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine-containing electronic cigarettes (ECs) 18 mg/mL with placebo tablets
Number of subjects: 458
Study 38884987 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline with standard dosing and nicotine-free ECs
Number of subjects: 458
Study 38884987 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablets with nicotine-free ECs
Number of subjects: 458
Study 38885033 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital mental health monitoring platform with wearable sensor (Fitbit Sense)
Number of subjects: 25
Study 38885066 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-task training
Number of subjects: 44
Study 38885066 — intervention group
Group type: COMPARATOR
Intervention: Single-task training
Number of subjects: 44
Study 38885086 — intervention group
Group type: EXPERIMENTAL
Intervention: 1L ibrutinib
Number of subjects: 0
Study 38885234 — intervention group
Group type: EXPERIMENTAL
Intervention: Glenzocimab (1000 mg/day for 3 days)
Number of subjects: 61
Study 38885234 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study 38885234 — intervention group
Group type: EXPERIMENTAL
Intervention: Glenzocimab
Number of subjects: 61
Study 38885246 — intervention group
Group type: EXPERIMENTAL
Intervention: Rucaparib 600 mg by mouth twice daily
Number of subjects: 12
Study 38885309 — intervention group
Group type: EXPERIMENTAL
Intervention: S-ICD models A209 and A219
Number of subjects: 1112
Study 38885397 — intervention group
Group type: EXPERIMENTAL
Intervention: Electromyographic (EMG) monitoring at the foot (posterior tibial nerve, flexor hallucis brevis muscle)
Number of subjects: 50
Study 38885397 — intervention group
Group type: COMPARATOR
Intervention: Electromyographic (EMG) monitoring at the hand (ulnar nerve, adductor pollicis muscle)
Number of subjects: 50
Study 38885397 — intervention group
Group type: EXPERIMENTAL
Intervention: Electromyographic (EMG) monitoring at the foot
Number of subjects: 50
Study 38885397 — intervention group
Group type: COMPARATOR
Intervention: Electromyographic (EMG) monitoring at the hand
Number of subjects: 50
Study 38885397 — intervention group
Group type: EXPERIMENTAL
Intervention: Electromyographic (EMG) monitoring at the hand and foot
Number of subjects: 50
Study 38885481 — intervention group
Group type: EXPERIMENTAL
Intervention: BAFF-R CAR T-cell therapy
Number of subjects: 1
Study 38885481 — intervention group
Group type: COMPARATOR
Intervention: CD19 CAR T-cell therapy
Number of subjects: 1
Study 38885482 — intervention group
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2-specific CTLs (1 of 4 escalating doses, containing 68.5% SARS-CoV-2-specific CD8+ CTLs/total cells)
Number of subjects: 30
Study 38885482 — intervention group
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2-specific CTLs
Number of subjects: 30
Study 38885482 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (observational group)
Number of subjects: 30
Study 38885598 — intervention group
Group type: EXPERIMENTAL
Intervention: IG1 (8 biweekly social support sessions)
Number of subjects: 121
Study 38885598 — intervention group
Group type: EXPERIMENTAL
Intervention: IG2 (6 biweekly social support sessions)
Number of subjects: 121
Study 38885598 — intervention group
Group type: COMPARATOR
Intervention: CG1 (standard care)
Number of subjects: 121
Study 38885598 — intervention group
Group type: COMPARATOR
Intervention: CG2 (standard care)
Number of subjects: 121
Study 38885672 — intervention group
Group type: EXPERIMENTAL
Intervention: Sovleplenib (300 mg once daily for 24 weeks)
Number of subjects: 188
Study 38885672 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 188
Study 38885672 — intervention group
Group type: EXPERIMENTAL
Intervention: Sovleplenib
Number of subjects: 188
Study 38885746 — intervention group
Group type: EXPERIMENTAL
Intervention: Synbiotic
Number of subjects: 180